中华肿瘤杂志最新文献

{"title":"[Expert consensus on combined screening for common cancers(2025 edition)].","authors":"K X Chen, W Q Chen, Y B Huang, Z Y Lyu, F F Song, C F Xia, Y J Xu, L Yang, C Sheng, Y C Zhang, P Wang, Y M Zhang, Y T Ji, J J Li, W X Li, J Wu, Q Y Jin, F J Song","doi":"10.3760/cma.j.cn112152-20250604-00255","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20250604-00255","url":null,"abstract":"<p><p>Malignant tumors (commonly referred to as cancer) represent a major global public health challenge and contribute significantly to the worldwide disease burden. Early screening plays a critical role in improving detection rates, enabling timely intervention, and enhancing patient survival rates. However, current cancer screening guidelines primarily focus on site-specific screening, which may not fully address the need for comprehensive early detection. A scientifically rational, multi-cancer screening approach offers several advantages: it optimizes the use of biological samples, reduces time costs for participants, enhances the efficiency and comprehensiveness of screening, and minimizes overall expenses. Such an approach also facilitates the rational allocation of healthcare resources, ultimately helping to reduce the societal burden of cancer. To address this need, the Cancer Epidemiology Committee of the Chinese Anti-Cancer Association has developed the Expert Consensus on Combined Screening for Common Cancers in China. This consensus integrates multidisciplinary expertise and synthesizes the latest domestic and international researches on cancer screening, early detection, and treatment for prevalent malignancies. Drawing upon China's unique demographic and healthcare context, as well as practical screening experiences, the consensus provides evidence-based recommendations on target populations, screening technologies, and procedural workflows for multi-cancer screening. These guidelines align with the principles and methodologies established by the World Health Organization (WHO), aiming to enhance the effectiveness of combined cancer screening in China, improve early detection rates, and provide a scientific foundation for national cancer prevention and control strategies.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"533-557"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Influence of varying frequency parameters in high-frequency oscillatory ventilation on the therapeutic efficacy of heavy ion radiotherapy in patients with thoracic and abdominal neoplasms: a prospective randomized controlled trial].","authors":"R H Song, Y Wang","doi":"10.3760/cma.j.cn112152-20250403-00147","DOIUrl":"10.3760/cma.j.cn112152-20250403-00147","url":null,"abstract":"<p><p><b>Objective:</b> To explore the effects and prognosis of heavy ion therapy for thoracic and abdominal malignant tumors under different frequency settings of high-frequency oscillatory breathing control. <b>Methods:</b> A prospective randomized controlled trial was conducted on 45 patients with thoracic and abdominal malignant tumors who received heavy ion therapy under high-frequency oscillatory ventilation (HFOV) control at Gansu Wuwei Tumour Hospital from January 2023 to December 2024. The patients were randomly divided into three groups by block randomization, with 15 patients in each group, and they received different HFOV frequency settings (6 Hz, 7 Hz and 8 Hz, i.e., 360 breaths/min, 420 breaths/min and 480 breaths/min), while other parameters were kept constant (oxygen concentration: 40%, mean airway pressure: 10 cmH₂O, amplitude: 6cm). The arterial blood gas, transcutaneous carbon dioxide partial pressure/transcutaneous oxygen partial pressure (TcPCO₂/TcPO₂), duration of HFOV ventilation, duration of invasive mechanical ventilation, length of hospital stay and complications of the patients under different frequency settings were analyzed. <b>Results:</b> Before and after treatment, there was no statistically significant difference in arterial blood gas parameters (PaCO₂, PaO₂), oxygenation index, blood lactate, bicarbonate ion) among the 6 Hz,7 Hz and 8 Hz HFOV frequency groups (all <i>P</i>＞0.05). At 30 minutes, 60 minutes, 120 minutes of treatment and at extubation, there was no statistically significant difference in TcPCO₂, TcPO₂, SpO₂ and heart rate among the 6 Hz, 7 Hz and 8 Hz HFOV frequency groups (all <i>P</i>＞0.05). The HFOV duration of the 6 Hz, 7 Hz and 8 Hz HFOV frequency groups was (131.7±8.4) minutes, (125.3±6.9) minutes and (115.7±10.5) minutes, respectively; the duration of invasive mechanical ventilation was (212.3±21.2) minutes, (190.7±14.8) minutes and (199.3±18.4) minutes, respectively; the tumor shrinkage rate was (53.1±6.1)%, (64.7±5.1)% and (63.0±6.2)%, respectively; and the hospital stay was (22.7±2.9) days, (22.3±3.1) days and (20.8±3.3) days, respectively. There was no statistically significant difference among the groups (all <i>P</i>＞0.05). Only one patient developed reversible hypercapnia, which returned to the normal range within 30 minutes after adjusting the invasive ventilator parameters. No treatment-related adverse events such as hypoxemia, radiation pneumonitis, or hemodynamic instability occurred in any of the subjects. <b>Conclusions:</b> HFOV management under heavy ion therapy for thoracoabdominal malignancies shows no significant changes in arterial blood gas analysis before and after treatment at different frequencies (6 Hz, 7 Hz, 8 Hz). Continuous monitoring of transcutaneous TcPCO₂/TcPO₂ is stable. The treatment process is safe, with few complications and good results.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"679-685"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression of SIPA1 in colorectal cancer and its impact on its biological behavior].","authors":"N Z Wang, L Zhang, J Chen, H Chen, R C Wang, C H Lu, Y F Ji","doi":"10.3760/cma.j.cn112152-20240812-00338","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20240812-00338","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objectives:&lt;/b&gt; To investigate the expression of signal-induced proliferation-associated 1 (SIPA1) in colorectal cancer tissues and its relationship with patient prognosis. To explore the effects of SIPA1 on proliferation and migration abilities, as well as the possible molecular mechanisms. &lt;b&gt;Methods:&lt;/b&gt; Using The Cancer Genome Atlas (TCGA) database to analyze the differential expression of SIPA1 and conduct survival analysis. Then, plotting receiver operating characteristic curve (ROC) and prognosis calibration curve analysis to assess the predictive capability and accuracy of SIPA1 for patient prognosis. Subsequently, verifying the expression levels of SIPA1 in tumor tissues and adjacent normal tissues using immunohistochemistry (IHC) and western blot (WB) assays(from March 1, 2023, to May 1, 2024, pathological specimens of five colorectal cancer patients were selected from the tissue bank of affiliated hospital of Nantong University. tissue microarrays were constructed using both cancerous tissues and adjacent normal tissues), and exploring the correlation between SIPA1 and clinical pathological parameters. Next, establishing SIPA1 stable knockdown cell lines in colorectal cancer cell lines DLD1 and HCT116, and assessing the biological behavior changes of tumor cells after SIPA1 knockdown through cell proliferation, invasion, and migration experiments. Validating the impact of SIPA1 on colorectal cancer cell proliferation &lt;i&gt;in vivo&lt;/i&gt; through subcutaneous xenograft experiments in nude mice. Exploring the potential pro-tumor mechanisms of SIPA1 through pathway enrichment analysis, and confirming these using WB experiments. The proliferation, invasion and migration of tumor cells were detected after adding PI3K activator. Lastly, conducting correlation analysis between SIPA1 and immune checkpoint, as well as the association with immune cells in the tumor microenvironment. &lt;b&gt;Results:&lt;/b&gt; Differential analysis showed that mRNA expression of SIPA1 in colorectal cancer tissues was significantly higher than that in adjacent normal tissues (&lt;i&gt;P&lt;/i&gt;＜0.05). Prognostic analysis indicated that patients with high expression of SIPA1 had poor overall survival (&lt;i&gt;P&lt;/i&gt;＜0.001), and the expression level of SIPA1was correlated with lymph node invasion (&lt;i&gt;P&lt;/i&gt;＜0.001) and N stage (&lt;i&gt;P&lt;/i&gt;＜0.05). ROC curve and prognosis calibration curve suggest that SIPA1 can effectively predict five-year survival rate of patients (AUC=0.7), and the predictive performance of the model is relatively accurate (&lt;i&gt;P&lt;/i&gt;＜0.001). WB experiments showed a significant increase in the expression level of SIPA1 protein in colorectal cancer specimens (&lt;i&gt;P&lt;/i&gt;＜0.001). Immunohistochemistry results indicated higher staining scores of SIPA1 in tumor tissues. &lt;i&gt;In vitro&lt;/i&gt; experiments demonstrated that SIPA1 knockdown significantly inhibited the proliferation, invasion, and migration capabilities of colorectal cancer cells. In DLD1 and HCT116 cells, the SIPA1-knockdown gro","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"657-668"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation between neutrophil extracellular traps and clinicopathological characteristics and prognosis of EGFR wild-type lung adenocarcinoma].","authors":"X X Zhang, R Zhang, Y W Guo, L Y Wu, J J Ma, X X Li","doi":"10.3760/cma.j.cn112152-20240929-00423","DOIUrl":"10.3760/cma.j.cn112152-20240929-00423","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the predictive value of neutrophil extracellular traps (NETs) on the prognosis of patients with epidermal growth factor receptor (EGFR) wild-type lung adenocarcinoma. <b>Methods:</b> A total of 132 surgical paraffin specimens of EGFR wild-type lung adenocarcinoma diagnosed at the Tumor Hospital Affiliated to Xinjiang Medical University from January 2016 to December 2023 and 12 pairs of cancer and paracancerous fresh tissues from patients with EGFR wild-type lung adenocarcinoma diagnosed in March-July 2024 were collected with their clinical information. Western blotting and immunofluorescence were used to detect the expression levels of citrullinated histone H3 (CitH3) and myeloperoxidase (MPO) in cancerous and paraneoplastic tissues. Immunohistochemistry was used to detect the infiltration of PD-L1, CD4⁺ T cells and CD8⁺ T cells in the tumors. The clinical and prognostic correlations between NETs and EGFR wild-type lung adenocarcinoma patients were analyzed. <b>Results:</b> The expression of MPO (<i>P</i>＜0.001) and CitH3 (<i>P</i>=0.009) was significantly increased in the tumors compared with the paracancerous tissues. The rate of high expression of NETs in cancer tissues was higher in patients with EGFR wild-type lung adenocarcinoma who were in stage Ⅲ and Ⅳ, with lymph node metastasis, distant metastasis, pleural invasion, high expression of Ki-67, low expression of CD8⁺ T, and lowered lymphocyte counts when compared to paraneoplastic tissues (<i>P</i>＜0.05). Patients were stratified based on TNM stage Ⅱb for prognostic analysis. Kaplan-Meier univariate analysis showed that the median overall survival (OS) (stage Ⅰ to Ⅱb: 47 vs 87 months; stage Ⅲ to Ⅳ: 27 months vs not reach) and the median disease-free survival (DFS) (stage Ⅰ to Ⅱb: 42 vs 78 months; stage Ⅲ to Ⅳ: 18 vs 39 months) of patients with high expression of NETs in stage Ⅰ to II b and stage Ⅲ to Ⅳ were lower than those with low expression (stage Ⅰ to Ⅱb: OS, <i>P</i>＜0.001; DFS, <i>P</i>＜0.001; stage Ⅲ to Ⅳ: OS, <i>P</i>=0.001; DFS, <i>P</i>=0.022). The OS (stage Ⅰ to Ⅱb: <i>HR</i>=3.513, 95% <i>CI:</i> 1.966-6.277, <i>P</i>＜0.001; stage Ⅲ to Ⅳ: <i>HR</i>=3.215, 95% <i>CI:</i> 1.324-7.806, <i>P</i>=0.010) and the DFS (stage Ⅰ to Ⅱb: <i>HR</i>=2.478 ,95% <i>CI:</i> 1.396-4.400, <i>P</i>=0.002; stage Ⅲ to Ⅳ: <i>HR</i>=2.248, 95% <i>CI:</i> 1.089-4.638, <i>P</i>=0.028) in the group with high expression of NETs in either stage Ⅰ to Ⅱb or stage Ⅲ to Ⅳ were significantly shorter than those in the group with low expression. <b>Conclusion:</b> The EGFR wild-type lung adenocarcinoma patients with high expression of NETs have relatively shorter DFS and OS, which are independent risk factors for the prognosis of patients with EGFR wild-type lung adenocarcinoma, and are likely to be the potential biomarkers for the diagnosis and treatment of EGFR wild-type lung adenocarcinoma.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"669-678"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on whole-course management of prostate cancer (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250212-00053","DOIUrl":"10.3760/cma.j.cn112152-20250212-00053","url":null,"abstract":"<p><p>Prostate cancer represents a prevalent malignancy within the male genitourinary system. In recent years, its incidence in China has gradually increased, becoming a significant public health issue. While early detection correlates strongly with improved prognosis, the majority of newly diagnosed prostate cancer patients in China are already in intermediate or advanced stages, precluding curative-intent interventions and contributing to marked survival disparities. The progression of prostate cancer is lengthy, typically encompassing diagnosis, treatment, progression, metastasis, and death, accompanied by a decline in quality of life. Personalized treatment plans should be developed based on the disease stage and patient preferences. In non-metastatic prostate cancer, where the tumor is confined to the prostate, surgery and radiotherapy are the primary treatments, supplemented by neoadjuvant and adjuvant therapies to delay metastasis. For metastatic prostate cancer, systemic therapy is prioritized to prolong survival. In metastatic hormone-sensitive prostate cancer, controlling androgen levels is crucial, while treatment options for metastatic castration resistant prostate cancer are relatively limited, necessitating individualized and precise treatment. During prostate cancer management, prostate-specific antigen levels are closely linked to prognosis and require monitoring. Bone metastasis, the most common site in prostate cancer patients, often triggers skeletal-related events, demanding effective prevention and management. Treatment-related adverse reactions are also a clinical challenge, requiring balanced risk-benefit assessments and judicious drug selection to preserve quality of life. Rapid advancements in screening technologies, surgical innovations, drug development, and China-specific epidemiological factors further complicate decision-making in holistic prostate cancer management. To optimize the standardization of prostate cancer diagnosis and treatment in China, the Genitourinary Oncology Committee of Chinese Anti-cancer Association synthesized global guidelines, clinical evidence and clinical expertise, and addressed critical challenges in the whole-course management of prostate cancer to formulate a multidisciplinary consensus. The expert consensus on whole-course management of prostate cancer (2025 edition) establishes standardized protocols to guide clinical practice, improve treatment outcomes, and enhance patient quality of life.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"617-634"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on the treatment of advanced lung cancer in elderly patients (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250326-00128","DOIUrl":"10.3760/cma.j.cn112152-20250326-00128","url":null,"abstract":"<p><p>Lung cancer exhibits the highest incidence and mortality among all malignancies in China, with incidence peaking after age 65. The growing elderly population has led to a significant increase in both the number and proportion of elderly lung cancer patients, necessitating standardized management for this group. The \"Consensus of Chinese experts on medical treatment of advanced lung cancer in the elderly (2022 edition)\" has provided essential clinical guidance in the past 2 years. However, evolving evidence-based medical findings and pharmaceutical advancements necessitate consensus updates. Against this backdrop, the Expert Committee on Geriatric Oncology Prevention and Treatment of the Chinese Society of Clinical Oncology (CSCO) has developed the \"Expert consensus on the treatment of advanced lung cancer in elderly patients (2025 edition). Based on the 2022 edition, this revision encompasses five key domains: definition and characteristics of the elderly population, comprehensive geriatric assessment for elderly advanced lung cancer patients, treatment of advanced non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) in elderly patients, and management of treatment-related adverse events. The core features of this consensus update are highlighted as follows: 1. Refined age-stratified management. Patients are categorized into three strata: younger-old (65-74 years), middle-old (75-84 years), and oldest-old (≥85 years), with precision management emphasized for each stratum. 2. Elevated role of comprehensive geriatric assessment. Positioning comprehensive geriatric assessment as an essential core tool throughout diagnosis and treatment. 3. Stratified precision treatment strategies. Treatment selection for NSCLC/ES-SCLC patients should balance efficacy and quality of life based on age stratification and comprehensive geriatric assessment. 4. Enhanced focus on drug safety and interactions. Prioritizing drug-drug interactions (DDIs) alongside safer drug selection and adverse event monitoring. Nine key recommendations were finalized to guide clinical practice, promoting rational and standardized management of advanced lung cancer in elderly patients in China.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"575-598"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on liquid biopsy-based multi-cancer early detection (2025 edition)].","authors":"W Q Chen, K X Chen, Y T He, W H Jia, Z H Liu, H X Ma, X P Miao, K F Pan, C Wu, C F Xia, J L Xing, Y J Xu","doi":"10.3760/cma.j.cn112152-20250605-00257","DOIUrl":"10.3760/cma.j.cn112152-20250605-00257","url":null,"abstract":"<p><p>Cancer stands as a significant global public health challenge, and cancer screening serves as a pivotal strategy for reducing its mortality. Presently, only a limited number of cancer types have appropriate screening methods available. Traditional single-cancer screening approaches are fraught with limitations, including invasiveness, low accuracy, and poor patient compliance. Multi-cancer early detection (MCED) leveraging liquid biopsy technology enables non-invasive and efficient early detection of multiple cancers by analyzing biomarkers such as cell-free DNA, cell-free RNA, proteins, and metabolites in blood and other bodily fluids. This innovative approach substantially broadens the spectrum of detectable cancers and enhances population coverage, showcasing immense potential for improving existing cancer screening strategies. This expert consensus comprehensively reviews the progress of liquid biopsy-based MCED, biomarker selection and detection technologies, the criteria for cancer type selection, research design and clinical utility evaluation, as well as implementation pathways. The overarching goal of this consensus is to offer scientific guidance for further research and the widespread adoption of MCED, thereby facilitating the continuous optimization of cancer screening strategies.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"558-574"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[MiR-1-3p inhibits mitophagy in esophageal squamous cell carcinoma by targeting SLC7A11].","authors":"S M Zhen, H R Zhang, J X Si, J Q Wang, Y Zhao, Y L Jia, L H Liu","doi":"10.3760/cma.j.cn112152-20240219-00078","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20240219-00078","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the effect of miR-1-3p on mitophagy in human esophageal squamous cell carcinoma (ESCC) cells and the related mechanisms. &lt;b&gt;Methods:&lt;/b&gt; The differentially expressed miRNAs in ESCC were screened using the GEO database. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to measure miR-1-3p expression in normal esophageal epithelial cells (HET-1A) and ESCC cell lines (TE1, KYSE30, KYSE150, KYSE410, Eca109). Bioinformatics tools were utilized to predict target genes of miR-1-3p, subcellular localization was confirmed by fluorescence in situ hybridization. The targeting relationship between miR-1-3p and SLC7A11 was validated using dual-luciferase reporter assay. Cell proliferation and apoptosis were detected by CCK8 assay and flow cytometry, respectively. Furthermore, experimental validation demonstrated that overexpression of SLC7A11 rescued the presence of the miR-1-3p/SLC7A11 axis. Confocal microscopy was used to detect changes in mitochondrial autophagic lysosomes, while transmission electron microscopy was employed to observe mitophagy and morphological alterations. Western blot was conducted to evaluate the expression of autophagy-related proteins LC3 and P62. Flow cytometry was used to measure mitochondrial membrane potential and reactive oxygen species (ROS). Immunohistochemistry was applied to assess SLC7A11 expression in 133 ESCC patient tissues and 115 normal esophageal epithelial tissues. The correlation between SLC7A11 expression level and clinicopathological features was analyzed. Survival analysis was performed using the Kaplan-Meier method, and Cox proportional hazard regression models were used for multivariate analysis. &lt;b&gt;Results:&lt;/b&gt; The expression of miR-1-3p in ESCC cells was significantly lower than that in HET-1A cells (&lt;i&gt;P&lt;/i&gt;＜0.05). SLC7A11 was a target gene of miR-1-3p. Transfection of miR-1-3p mimic inhibited the proliferation of ESCC cells. CCK-8 assay results showed that the proliferative capacity of KYSE30 and KYSE410 cells in the miR-1-3p mimic group (absorbance values: 2.88±0.24 and 2.88±0.18, respectively) was significantly lower than that in the miRNA mimic negative control (NC) group (3.94±0.27, &lt;i&gt;P&lt;/i&gt;＜0.001; 4.20±0.21, &lt;i&gt;P&lt;/i&gt;＜0.001). Meanwhile, the proliferative capacity of KYSE30 and KYSE410 cells in the miR-1-3p mimic+SLC7A11-overexpression (OE) group (absorbance values: 3.57±0.15 and 3.60±0.13, respectively) was significantly higher than that in the miR-1-3p mimic +empty vector (EV) group (2.54±0.10, &lt;i&gt;P&lt;/i&gt;＜0.001, 2.36±0.16, &lt;i&gt;P&lt;/i&gt;＜0.001). Additionally, transfection of miR-1-3p mimic promoted apoptosis. Flow cytometry results demonstrated that the apoptosis rates of KYSE30 and KYSE410 cells in the miR-1-3p mimic group [(9.22±0.05)% and (6.55±0.37)%, respectively] were significantly higher than those in the miRNA mimic NC group [(0.81±0.17)%,&lt;i&gt;P&lt;/i&gt;＜0.001); (1.04±0.12)%, &lt;i&gt;P&lt;/i&gt;＜0.001]. Conversely, the apoptosis rates of KYSE30 and KYSE410 cells ","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"645-656"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical expert consensus on the application of long-acting granulocyte colony-stimulating factor in gynecologic malignancies (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20241105-00477","DOIUrl":"10.3760/cma.j.cn112152-20241105-00477","url":null,"abstract":"<p><p>Ovarian cancer, cervical cancer, and endometrial cancer are the three major malignant tumors in gynecologic oncology, with an increasing incidence rate in recent years. Chemotherapy, radiotherapy, immunotherapy, and targeted therapy remain the mainstays of treatment; however, all may cause varying degrees of myelosuppression, with neutropenia being the most common adverse effect. Notably, the incidence of grade ≥3 neutropenia among gynecologic oncology patients undergoing antitumor therapy is significantly higher than that in patients with other solid tumors, leading to increased risk of severe infections, prolonged hospitalization, and potentially life-threatening complications. Therefore, effective prevention and management of neutropenia are crucial to ensuring treatment adherence and maintaining patients' quality of life. A growing body of evidence has demonstrated the clinical value of long-acting granulocyte colony-stimulating factor (G-CSF) in the prevention and management of neutropenia. Based on the latest evidence in evidence-based medicine, this expert consensus provides an overview of neutropenia commonly encountered during chemoradiotherapy in patients with gynecologic malignancies and highlights its potential impact on treatment outcomes. It then systematically introduces the long-acting G-CSF currently approved by the U.S. Food and Drug Administration (FDA) and Chinese regulatory authorities. The consensus further elaborates on the clinical applications of long-acting G-CSF in the prevention of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN), and presents corresponding recommendations. Additionally, it outlines the differentiated use of long-acting G-CSF in primary and secondary prophylaxis, along with recommended dosing regimens and administration strategies based on recent literature. Potential adverse effects and corresponding management strategies of long-acting G-CSF are also systematically reviewed. To promote the standardized use of long-acting G-CSF in gynecologic cancer treatment, this 2025 edition of the expert consensus has been jointly developed by leading domestic experts, providing comprehensive guidance and evidence-based recommendations for rational clinical use in this field.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"635-644"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250524-00240","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20250524-00240","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Breast cancer is the most common malignancy among women worldwide, with relatively high morbidity and mortality rates among Chinese women, posing a serious threat to female health. HR+/HER-2- breast cancer is the most common subtype, accounting for approximately 70% of all breast cancers. The vast majority of patients are diagnosed with early breast cancer (EBC) at initial presentation. Stage Ⅱ-Ⅲ EBC constitutes a substantial proportion of cases among Chinese patients, with a significantly younger age of onset observed nationally. Even after standard endocrine therapy, patients still face short-term and long-term recurrence risks, and the risk of recurrence persists lifelong. In recent years, large-scale real-world studies from the National Cancer Center and other institutions, both domestically and internationally, have shown that for stage Ⅱ-Ⅲ HR+/HER-2- EBC patients, those with lymph node positivity and lymph node negative patients with high-risk factors have a significantly higher risk of recurrence and death. The postoperative 5-year recurrence rate for lymph node negative patients with high-risk factors can reach 15%, similar to the recurrence rate of N1 patients. These findings have updated the clinical understanding of defining high-risk patients and raised new requirements for EBC recurrence risk assessment and definition. On the other hand, the clinical management of recurrence risk in early HR+/HER-2- breast cancer has consistently received significant attention. From the initial adjuvant chemotherapy to the entire process of adjuvant endocrine therapy, in recent years, with the publication of clinical trial results for novel targeted agents such as CDK4/6 inhibitors (CDK4/6i) and PARP inhibitors (PARPi) and the subsequent approval of their indications, the treatment paradigm for HR+/HER-2- EBC has gradually evolved from traditional endocrine therapy to a selective strategy of intensified treatment combining endocrine therapy with targeted agents. This underscores the critical importance of precise recurrence risk assessment and optimization of treatment decisions. To assist clinicians in scientifically and accurately assessing recurrence risk and tailoring individualized intensified adjuvant treatment regimens for patients, the Breast Cancer Expert Committee of the National Cancer Quality Control Center, the Professional Committee of Drug Clinical Research of Chinese Anti-Cancer Association, and the Professional Committee of Breast Cancer of the Chinese Anti-Cancer Association, incorporating advances in clinical research on early breast cancer both domestically and internationally and expert opinions, have formulated the \"Consensus on Recurrence Risk and Clinical Management of HR+/HER-2- Early Breast Cancer(2025 edition)\". It aims to provide a standardized reference for recurrence risk stratification and clinical management of HR+/HER-2-EBC patients, further enhancing patient treatment benefits and quality of life, and maximizin","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"599-616"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}